Surgery most effective treatment of metabolic liver disease
King's College LondonMetabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease.
Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.
The underrepresentation of female research subjects has been documented from clinical trials down to sources for cell cultures. Now, researchers out of Marquette University in Milwaukee have found that in exercise research, this inequity correlates with the gender of the researchers conducting the study.
Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.
UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CART-cell therapy.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The National Institutes of Health trial to evaluate the mpox (previously known as monkeypox) vaccine JYNNEOS has now entered the next stage and is studying the immune responses to and the safety of the vaccine in adolescents. The George Washington University is one of 18 clinical trial sites across the United States that have launched this stage testing the JYNNEOS vaccine.
The immuno-oncology (IO) clinical trial landscape is shifting in new directions. While the number of total clinical trials is down, there are healthy signs of innovation.
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023. The studies, which describe results from a novel FGFR inhibitor and from new PARP/ATR inhibitor combinations, were featured in a plenary session highlighting novel biomarker-driven molecularly targeted therapy trials.
Research led by Roswell Park's Sarbajit Mukherjee, MD, MS, shows that a new chemotherapy combination — trifluridine/tipiracil (FTD/TPI) and oxaliplatin — is well tolerated and has activity among patients with esophageal cancer.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5 percent overall response rate.
Researchers have made huge strides in ensuring that red blood cell substitutes – or artificial blood – are able to work safely and effectively when transfused into the bloodstream.
An international phase 3 clinical trial led by physicians at Washington University School of Medicine in St. Louis has shown that the investigational drug motixafortide — when combined with the standard therapy for mobilizing stem cells — significantly increases the number of stem cells that can be harvested, compared with treatment with the standard agent alone.
The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.
Results from a preclinical study from Penn Medicine, presented at the AACR Annual Meeting 2023, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.
The university is participating in the effort to determine the efficacy of what could be the first vaccine to prevent Lyme disease in children ages 5 to 17
Ochsner Health is one of 20 sites in the U.S. participating in the PROMISE II clinical trial, which was recently published in the New England Journal of Medicine.
A large clinical trial of more than 8,700 patients published in the New England Journal of Medicine concluded that the sex of a donor has no effect on the survival of recipients of red blood cell transfusions.
UC San Francisco interventional cardiologists and interventional echocardiographers recently performed two novel minimally invasive cardiac procedures for the first time in the health system.
Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.
Researchers tested whether using open-label placebo could increase the efficacy of methadone treatment for people undergoing care for opioid use disorder.
A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters pulmonary and myocardial cells through binding of its spike protein to the human angiotensin-converting enzyme 2 (ACE2). ACE2 is a vital enzyme that controls blood pressure and blood flow to multiple organs, including the lungs, heart and kidneys.
De acordo com uma pesquisa conduzida pela Aliança para Ensaios Clínicos em Oncologia e o Centro de Câncer da Mayo Clinic, pacientes com diversos tumores em um seio podem ser capazes de evitar uma mastectomia se os tumores puderem ser removidos enquanto uma quantidade suficiente de tecido mamário puder ser preservada.
قد تتمكن النساء المصابات بأورام متعددة في أحد الثديين من تجنب استئصاله إذا أمكن استئصال هذه الأورام مع الاحتفاظ بأنسجة ثدي كافية، وذلك وفقًا لبحث قاده التحالف الطبي للتجارب السريرية في علم الأورام ومركز مايو كلينك الشامل للسرطان.
De acuerdo con la investigación dirigida por la Alianza para Ensayos Clínicos en Oncología y el Centro Oncológico Integral de Mayo Clinic, las pacientes que tengan varios tumores en una sola mama podrían evitar una mastectomía si los tumores se pueden extraer dejando bastante tejido mamario.
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) physicians and scientists are presenting research studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting at the Orange County Convention Center in Orlando, Florida, April 14 to 19th.
A trio of premier Southwest biomedical research centers — HonorHealth Research Institute, City of Hope and the Translational Genomics Research Institute (TGen), part of City of Hope — have developed a more precise method that may help determine when it is best to surgically remove of pancreatic cancer tumors.
In this randomized clinical trial, anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia. Future research should assess anakinra in patients with less severe pneumonia.
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza.
Read about cutting-edge cancer research centered around elephant genes, a new clinical trial, and grants to study vaccination hesitance in the Mountain West as well as chronic lymphocytic leukemia.
In an analysis of published clinical trials, investigators found that phototherapy—or exposure to sessions of bright light—may be a promising non-pharmacological intervention for lessening symptoms of dementia.
Hackensack University Medical Center is the only site in New Jersey that is participating in the ROADSTER 3 clinical trial to assess real-world outcomes for patients with carotid artery disease who have an average surgical risk and undergo a minimally invasive surgical procedure called transcarotid artery revascularization (TCAR).
Spinal cord stimulation (SCS) has demonstrated effectiveness for neuropathic pain. Unfortunately, some patients report inadequate long-term pain relief. Patient selection is emphasized for this therapy; however, the prognostic capabilities and deployment strategies of existing selection techniques, including an SCS trial, have been questioned.
The NANT pediatric cancer consortium at Children’s Hospital Los Angeles has published results of a phase 1 trial for high-risk neuroblastoma.
A significant clinical trial under the direction of Michael Kappelman, MD, MPH, professor of pediatrics at UNC School of Medicine, found that patients receiving the tumor necrosis factor inhibitor adalimumab combined with a low dose of methotrexate, a second immunosuppressant, did better than those treated with infliximab alone. Patients who received infliximab, another tumor necrosis factor inhibitor, had similar outcomes with or without methotrexate.
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.
A groundbreaking human clinical trial published in the Journal of Biochemistry and Biotechnology reveals AstraGin®'s significant impact on various factors related to gut health in patients with Ulcerative Colitis (UC).
More than 75% of patients facing amputation from the most severe form of peripheral artery disease were able to keep their limb after an innovative treatment as part of a multicenter study published in the . The alternative to amputation, known as “limb salvage,” for patients with chronic limb-threatening ischemia (CLTI) came from the PROMISE II clinical trial.
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.
A newly published study paves the way for some patients with testicular cancer to avoid chemotherapy and radiation.
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
A study, co-led by University Hospitals Harrington Heart & Vascular Institute, could lead to the first FDA approval of a therapy giving thousands of patients hope for an alternative to amputation.
Antiphospholipid syndrome is a understudied autoimmune disease that is nevertheless a leading causes of deadly blood clots and late-term pregnancy loss. An international study led by the University of Michigan researchers Ray Zuo, M.D., and Jason Knight, M.D., Ph.D., has discovered a new class of functional autoantibodies in APS patients that contributes to the disease's development and the systemic inflammation it induces.
Patients who have multiple tumors in one breast may be able to avoid a mastectomy if the tumors can be removed while leaving enough breast tissue, according to research led by the Alliance in Clinical Trials in Oncology and Mayo Clinic Comprehensive Cancer Center.
Cedars-Sinai and BlackDoctor.org will host a virtual community conversation about the importance of increasing diverse representation in medical research.
From septic shock to sticker shock. Keep up with this ever-growing, changing sector. Below are some of the latest stories on healthcare on Newswise.
The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer (EC).